



2018 Annual Meeting Scholar-in-Training Awards

The AACR is proud to offer Scholar-in-Training Awards to enable the participation of meritorious early-career scientists at the Annual Meeting 2018. Since its inception in 1986, the AACR Annual Meeting Scholar-in-Training Award program has provided more than 4,500 grants to young investigators and has received support from more than 55 cancer research foundations, corporations, individuals and other organizations dedicated to the fight against cancer. This year, 21 organizations or individuals generously provided the funding to support this program.

The names and affiliations of the 2018 Scholar-in-Training Award recipients, along with the abstract numbers and titles of their abstracts, are listed below.

2018 AACR Scholar-in-Training Awards

AACR has graciously both donated and distributed funds received to support early-career investigators who will be presenting meritorious abstracts at the AACR Annual Meeting 2018.

Yashar S. Niknafs, PhD, University of Michigan, Ann Arbor, MI. **Abstract 4982.** Oncogenic role of *THOR*, a conserved cancer/testis long noncoding RNA.

Mellissa J. Nixon, PhD, Vanderbilt University, Nashville, TN. **Abstract 2982.** Somatic TP53 mutations alter the immune microenvironment after chemotherapy in breast cancer.

Hitoshi Ohtani, PhD, Van Andel Research Institute, Grand Rapids, MI. **Abstract 2993.** A switch in epigenetic silencing mechanisms of endogenous retroviruses during human genome evolution.

Ethel R. Pereira, PhD, Massachusetts General Hospital/Harvard Medical School, Boston, MA. **Abstract 3022.** Lymph node metastasis in solid tumors: A marker or driver of disease progression?

Brian J. Abraham, PhD, MIT Whitehead Institute for Biomedical Research, Cambridge, MA. **Abstract 971.** Three-dimensional gene regulatory landscapes in normal and cancer cells.

Mustafa M. Basree, MS, Kentucky College of Osteopathic Medicine, Pikeville, KY. **Abstract 2242.** Breastfeeding protects against pro-tumorigenic changes in the mammary gland by limiting epithelial luminal progenitor cell expansion.

Roman Camarda, BS, University of California San Francisco, San Francisco, CA. **Abstract 2398.** Tumor cell-adipocyte gap junctions activate lipolysis in breast cancer.

Valerio Embrione, MS, The Ohio State University, Columbus, OH. **Abstract 476.** A human scFv as a tool to understand the biogenesis of a subset of oncogenic microRNAs.

Merit L. Goodman, BS, University of Kansas Medical Center, Kansas City, KS. **Abstract 1800.** Progesterone receptor attenuates STAT1-mediated interferon signaling in breast cancer.

Robert Gueth, PhD, New Mexico State University, Las Cruces, NM; California State University, Northridge, CA. **Abstract 4998.** Targeting DHPS to abrogate TGF β -induced metastasis in breast cancer.

Peter C. Hart, PhD, University of Chicago, Chicago, IL. **Abstract 5474**. Activity of the S1P pathway promotes ovarian cancer and serves as a novel metabolic target of metformin.

Sisi He, MS, University of Illinois Urbana-Champaign, Champaign, IL. **Abstract 199**. Host CYP27A1 expression is essential for ovarian cancer progression.

Lauren M. Hurwitz, MHS, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. **Abstract 4947**. Aspirin use and risk of lethal prostate cancer in the Atherosclerosis Risk in Communities cohort.

Lauren Jin Suk Joo, BS, Kolling Institute of Medical Research, The University of Sydney, St. Leonards, NSW, Australia. **Abstract 501**. A RET-related microRNA, miR-153-3p, acts as a tumor suppressor in medullary thyroid carcinoma (MTC) via S6K signaling.

Aaron B. Koenig, MS, The Ohio State University College of Medicine, Columbus, OH. **Abstract 5400**. A comprehensive analysis of the interactome of miR-21, an established oncomir, by Argonaute-CLIP analysis identifies novel conserved and species-specific targets of miR-21 in human liver and hepatocellular carcinoma.

Dragomir B. Krastev, PhD, Institute of Cancer Research, London, United Kingdom. **Abstract 1360**. A PARylation biosensor genetic screen to identify novel PARylation targets.

Steve Seung-Young Lee, PhD, The University of Chicago, Chicago, IL. **Abstract 3032**. Quantitative three-dimensional imaging cytometry of tumor immune microenvironment.

Kah Suan Lim, PhD, Dana-Farber Cancer Institute, Boston, MA. **Abstract 333**. USP1 is required for replication fork stability in BRCA1-deficient tumors.

Evan C. Markegard, BS, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA. **Abstract 5520**. Oncogenic RTK signaling inhibits Spred1/NF1 to sustain constitutive Ras/MAPK signaling.

Kevin C. Miller, BS, Mayo Clinic, Rochester, MN. **Abstract 3909**. HDAC inhibition in combination with MEK or BCL-2 inhibition as novel therapeutic strategies in multiple myeloma.

Stephen Mok, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX. **Abstract 2984**. Effects of anti-CTLA-4 and anti-PD-1 on memory T-cell differentiation and resistance to tumor relapse.

Alexander H. Morrison, BA, University of Pennsylvania, Philadelphia, PA. **Abstract 4940**. Nonredundant roles for immune checkpoint blockade and agonistic CD40 in mediating T-cell responses in pancreatic ductal adenocarcinoma.

Tarek H. Mouhieddine, MD, Dana-Farber Cancer Institute, Boston, MA. **Abstract 2954**. Immunomodulator maintenance post autologous stem cell transplant predicts better outcome in multiple myeloma patients with clonal hematopoiesis of indeterminate potential.

Nethaji Muniraj, PhD, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD. **Abstract 1335**. Withaferin A induces nonprotective autophagy in a STK11-independent manner and mediates breast cancer inhibition via energetic impairment.

Manali S. Phadke, PhD, Moffitt Cancer Center, Tampa, FL. **Abstract 3973**. Dabrafenib suppresses the growth of *BRAF-WT* cancers through inhibition of novel targets Nek9 and Cdk16.

Evanthia T. Roussos Torres, MD, PhD, Johns Hopkins University, Baltimore, MD. **Abstract 4965**. Entinostat transforms the suppressive tumor microenvironment of breast cancer and promotes survival and anti-responses when combined with checkpoint inhibition.

Madhav Sankunny, PhD, Cleveland Clinic Foundation, Cleveland, OH. **Abstract 317**. Role of KLLN in DNA damage-induced apoptosis is associated with the regulation of p53 phosphorylation and acetylation in breast cancer cells.

Steven D. Scoville, PhD, The Ohio State University, Columbus, OH. **Abstract 4729**. The aryl hydrocarbon receptor directly regulates microRNA-29b to inhibit human natural killer cell development and function in acute myeloid leukemia.

Xiang Shu, PhD, Vanderbilt University Medical Center, Nashville, TN. **Abstract 3222**. Evaluation of associations between circulating proteins and breast cancer risk using genetic variants.

Vindhya Vijay, MS, University of Florida, Gainesville, FL. **Abstract 4955**. Heterogeneous nuclear ribonucleoprotein C as a novel therapeutic target for acute myeloid leukemia.

2018 AACR- American Brain Tumor Association Scholar-in-Training Awards

The American Brain Tumor Association has graciously donated funds to support young investigators who will be presenting high-quality abstracts in brain cancer research for both primary and secondary (metastatic) brain tumors at the AACR Annual Meeting 2018.

Damian A. Almiron Bonnin, BA, Geisel School of Medicine at Dartmouth, Hanover, NH. **Abstract 141**. HEY1-mediated inhibition of glioma stem cell proliferation is associated with restoration of glioma stem cell division asymmetry and transcriptional repression of PDGFRA.

Samirkumar B. Amin, MBBS, PhD, The Jackson Laboratory for Genomic Medicine, Farmington, CT. **Abstract 1176**. Genomic profiling of canine glioma: Comparative analyses with respect to drivers of human glioma.

Peiwen Chen, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX. **Abstract 117**. Lysyl oxidase secreted by PTEN-deficient glioblastoma cells recruits macrophages and promotes malignant growth.

Islam Hassan, MD, The University of Texas MD Anderson Cancer Center, Houston, TX. **Abstract 2955**. A radiomic-based MRI phenotype is uniquely associated with hypermutated genotype in gliomas.

Mohammad Belayat Hossain, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX. **Abstract 3205**. Histone tyrosine phosphorylation determines glioblastoma cell survival.

Yunpeng Liu, MS, Massachusetts Institute of Technology, Cambridge, MA. **Abstract 928**. Regulatory heterogeneity in glioblastoma multiforme informs novel drug target discovery.

2017 AACR-Aflac, Inc. Scholar-in-Training Awards

Support for AACR Scholar-in-Training Awards is part of Aflac's generous support of activities for early-career scientists within the AACR. These awards support early-career investigators who will be presenting meritorious abstracts at the AACR Annual Meeting 2018.

Kristin G. Anderson, PhD, Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA. **Abstract 2555**. Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in solid tumors.

Vrushank Dharmesh Bhatt, MS, Rutgers University, New Brunswick, NJ. **Abstract 4969**. Autophagy modulates lipid metabolism to support Liver Kinase B1 (LKB1) - deficient lung tumor growth.

Alisson Clemenceau, MS, Institut universitaire de cardiologie et de pneumologie de Québec, Québec, QC, Canada. **Abstract 2351**. Transcriptome-wide association study reveals candidate causal genes for lung cancer.

Rosario I. Corona, PhD, Cedars-Sinai Medical Center, Los Angeles, CA. **Abstract 395**. Identifying the functional drivers of noncoding somatic mutations in ovarian cancer.

Prasenjit Dey, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX. **Abstract 777**. Malic enzyme 3 as a collateral lethality target in pancreatic cancer.

Adam M. Farkas, PhD, Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, New York, NY. **Abstract 4745**. Tim-3 and TIGIT mark NK and T cells susceptible to effector dysfunction in human bladder cancer.

Paul Geeleher, PhD, University of Chicago, Chicago, IL. **Abstract 4271**. Most expression quantitative trait loci discovered in tumors cannot be attributed to cancer cells.

Alissa D. Guarnaccia, BS, Vanderbilt University, Nashville, TN. **Abstract 972**. Defining the molecular context of MYC and WDR5 at chromatin.

Ann Hanna, BS, University of Alabama at Birmingham, Birmingham, AL. **Abstract 4043**. A novel role for Hedgehog signaling in macrophage-mediated immune evasion.

Jianguo Huang, PhD, Duke University Medical Center, Durham, NC. **Abstract 516**. Long noncoding RNA NEAT1 promotes lung metastasis of soft tissue sarcoma.

Sunil Kumar Joshi, BA, Knight Cancer Institute, Oregon Health & Science University (OHSU), Portland, OR. **Abstract 970**. Transforming NTRK2 and NTRK3 mutations as potential drivers of leukemia.

Xianzhi Lin, PhD, Cedars-Sinai Medical Center, Los Angeles, CA. **Abstract 514**. Lncrna *uca1* interacts directly with angiomin to activate Hippo-YAP signaling in epithelial ovarian cancer.

Mingen Liu, BA, University of Pennsylvania, Philadelphia, PA. **Abstract 4962**. Metabolic rewiring of macrophages by CpG stimulates anti-tumor activity that overrides CD47-resistance in pancreatic cancer.

Megan Ludwig, BS, University of Michigan, Ann Arbor, MI. **Abstract 964**. Genome-wide CRISPR screen identifies potential therapeutic combination of EGFR and FGFR inhibitors in oral cancer.

Disha Malani, MS, Institute for Molecular Medicine Finland, Helsinki, Finland. **Abstract 3899**. Discovery and clinical implementation of individualized therapies in acute myeloid leukemia based on *ex vivo* drug sensitivity testing and multi-omics profiling.

Neelam Mukherjee, PhD, The University of Texas Health Science Center at San Antonio, San Antonio, TX. **Abstract 3792**. Intratumoral CD56^{bright} natural killer cells are associated with improved survival in bladder cancer.

Aritro Nath, PhD, University of Minnesota , Minneapolis, MN. **Abstract 3897**. Pharmacogenomic landscape of long non-coding RNAs in human cancers.

Caitlin A. Nichols, BS, Dana-Farber Cancer Institute, Boston, MA. **Abstract 3003**. Loss of heterozygosity of essential genes represents a novel class of cancer vulnerabilities.

Thao Nguyen D. Pham, PhD, Northwestern University, Chicago, IL. **Abstract 2989**. BET inhibitors induce Rac1-dependent MNK and eIF4E phosphorylation in cancer cells.

Liam R. Poynter, MB BS BSc.(Hons) MRCS, Imperial College London, London, United Kingdom. **Abstract 3203**. Modulation of cellular phospholipids correlates with tumor regression grade and radio resistance in rectal cancer.

Vaishnavi Sambandam, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX. **Abstract 2977**. PI3K/mTOR pathway inhibition induces Aurora B mediated cell death in *NOTCH1* mutant head and neck squamous (HNSCC) cells.

Ronald F. Siebenaler, BS, University of Michigan, Ann Arbor, MI. **Abstract 4370**. Regulation of AGO2-KRAS interaction through epidermal growth factor receptor.

Guan-Yu Xiao, PhD, UT Southwestern Medical Center, Dallas, TX. **Abstract 966**. Oncogenic signaling pathways differentially regulate clathrin-mediated endocytosis in cancer cells.

Hanghang Zhang, PhD, Fels Institute for Cancer Research, Temple University School of Medicine, Philadelphia, PA. **Abstract 2952**. Targeting CDK9 reactivates epigenetically silenced genes in cancer.

Xiaowen Zhang, PhD, UT Health Science Center at San Antonio, San Antonio, TX. **Abstract 2990**. Attenuation of RNA polymerase II pausing mitigates BRCA1-associated R-loop accumulation and tumorigenesis.

Yiqing Zhao, PhD, Case Western Reserve University, Cleveland, OH. **Abstract 2379**. PTPRT pseudo-phosphatase domain is a denitrase that contributes to its tumor suppressor function.

Asaf Zviran, PhD, New York Genome Center, New York, NY. **Abstract 3247**. Genome-wide cell-free DNA mutation integration for sensitive cancer detection.

2018 AACR Scholar-in-Training Award in Memory of Nina Becka

Funds have been graciously donated in memory of Nina Becka to the AACR to support an early-career investigator who will be presenting a meritorious abstract on Ewing's sarcoma research at the AACR Annual Meeting 2018.

Lillian M. Guenther, MD, Dana-Farber Cancer Institute, Boston, MA. **Abstract 1629**. Targeting resistance mechanisms to CDK4/6 inhibitors in Ewing sarcoma with an IGF1R inhibitor drug combination strategy.

2018 AACR-June L. Biedler Scholar-in-Training Awards

These awards are presented to authors of meritorious abstracts in the field of drug resistance to be presented at the AACR Annual Meeting 2018. These awards are made possible through the Estate of Dr. June L. Biedler to increase public understanding of basic cancer research. The late Dr. Biedler was a dedicated member of

AACR and a distinguished scientist at Memorial Sloan Kettering Cancer Center. Dr. Biedler believed that science communication is a cornerstone to the acceleration of progress.

Gloria V. Echeverria, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX.

Abstract 212. High-resolution barcoding in patient-derived xenografts of triple-negative breast cancer reveals reversible chemoresistance conferred by non-mutational mechanisms.

Haichuan Hu, MD, PhD, Massachusetts General Hospital Cancer Center, Charlestown, MA. **Abstract 4954.** Decoding tumor microenvironment to enhance NSCLC targeted therapy.

Shih-Bo Huang, MS, University of Texas Health San Antonio, San Antonio, TX. **Abstract 945.** Novel role for SIRT1 in non-canonical activation of AR signaling.

Robert D. Leone, MD, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD. **Abstract 4963.** Targeting glutamine metabolism as a means of enhancing anti-tumor T cell responses.

Kelly G. Paulson, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA. **Abstract 2980.** Single cell RNA sequencing reveals AML immunoediting under pressure from engineered T cell therapy.

Chao Zhang, MS, The Moffitt Cancer Center & Research Institute, and The College of Medicine, University of South Florida, Tampa, FL. **Abstract 3025.** Ligand-independent EphA2 signaling drives an amoeboid phenotype that promotes melanoma brain metastasis development.

2018 AACR-Bristol-Myers Squibb Oncology Scholar-in-Training Awards

Bristol-Myers Squibb Oncology has graciously donated funds to support early-career investigators who will be presenting meritorious abstracts at the AACR Annual Meeting 2018.

Nicolás Anselmino, BS, University of Buenos Aires, CABA, Argentina. **Abstract 4180.** Game-changing restraint of Ros-damaged phenylalanine, upon tumor metastasis.

Huai-Chin Chiang, PhD, UT Health Science Center at San Antonio, San Antonio, TX. **Abstract 4460.** *BRCA1*-associated R-loop accumulation at noncoding putative ER α enhancer area regulates expression of adjacent genes.

Md Kamrul Hasan, PhD, Moores Cancer Center, University of California San Diego, San Diego, CA. **Abstract 3492.** Wnt5a induces ROR1 to associate with DOCK1 and promote growth of breast cancer cells.

Leila Kokabee, PhD, The State University of New York at Albany, Rensselaer, NY. **Abstract 5170.** The effect of vitamin K on aggressiveness, lipid metabolism and gene expression in triple-negative breast cancer cells.

Venkatesh Kolluru, PhD, University of Louisville, Louisville, KY. **Abstract 1328.** Cadmium-induced endoplasmic reticulum stress causes defective autophagy in human prostate carcinogenesis.

Merrin Man Long Leong, MS, The University of Hong Kong, Hong Kong. **Abstract 5521.** Functional characterization of a candidate tumor suppressor gene, *Mirror image polydactyly 1*, in nasopharyngeal carcinoma.

Liqian Ma, BS, University of Illinois at Urbana Champaign, Urbana, IL. **Abstract 2133.** Mechanisms by which 27-hydroxycholesterol promotes breast cancer metastasis.

Lindsey C. Reynolds, MS, University of Louisville, Louisville, KY. **Abstract 369**. The retinoblastoma protein regulates glucose metabolism in lung cancer.

Jennifer M. Rosenbluth, MD, PhD, Harvard Medical School, Boston, MA. **Abstract 989**. Organoid cultures from normal and cancer-prone human breast tissues preserve complex epithelial lineages and can form chimeric mammary glands in vivo.

Brandi P. Smith, MS, University of Illinois at Urbana-Champaign, Champaign, IL. **Abstract 3012**. Urban neighborhood and residential factors associated with breast cancer in African American women: A systematic review.

Na-Young Song, PhD, NCI-Frederick, Frederick, MD. **Abstract 5008**. Crosstalk between epithelial-IKK α -deletion and symbiotic bacterial-fungal infection in skin carcinogenesis.

Katie A. Thies, PhD, Medical University of South Carolina, Charleston, SC. **Abstract 49**. Stromal platelet derived growth factor receptor (PDGFR β) signaling: A novel therapeutic target for breast cancer brain metastasis (BCBM).

Alex H. Wagner, PhD, Washington University in Saint Louis, Saint Louis, MO. **Abstract 3282**. Standardization and coordination of variant interpretation knowledgebases improves clinical genome actionability.

Melanie Weigert, PhD, University of Chicago, Chicago, IL. **Abstract 4379**. Oncolytic adenovirus type 5 induces a novel form of programmed necrosis.

Lisa Welter, MS, University of Southern California, Los Angeles, CA. **Abstract 2963**. Characterization of disease evolution in sequential sampled metastatic breast cancer using liquid biopsy.

2018 AACR Scholar-in-Training Awards in Memory of Cecelia Cantalupi

Funds have been graciously donated in memory of Cecelia Cantalupi to the AACR to support early-career investigators who will be presenting meritorious abstracts on lung cancer research at the AACR Annual Meeting 2018.

Runzhe Chen, MD, The University of Texas MD Anderson Cancer Center, Houston, TX. **Abstract 4686**. T cell repertoire evolution from the normal lung to invasive lung adenocarcinoma.

Loukia G. Karacosta, PhD, Stanford University, Stanford, CA. **Abstract 4997**. Identifying dynamic EMT states and constructing a proteomic EMT landscape of lung cancer using single cell multidimensional analysis.

2018 AACR Margaret Foti Scholar-in-Training Awards in Pediatric Cancer Research

Through a generous gift of the Margaret Foti Foundation, these awards recognize outstanding young investigators for their meritorious work in pediatric cancer research and support their attendance to the AACR Annual Meeting 2018.

Kristopher R. Bosse, MD, Children's Hospital of Philadelphia, Philadelphia, PA. **Abstract 4636**. The antibody-drug conjugate D3-GPC2-PBD potently eradicates neuroblastoma patient-derived xenografts.

Maggie H. Chasse, MS, Van Andel Institute, Grand Rapids, MI. **Abstract 4634**. Mithramycin amplifies the imbalance between the BAF and PRC2 complexes to drive apoptosis in rhabdoid tumor.

Catherine Drummond, PhD, St. Jude Children's Research Hospital, Memphis, TN. **Abstract 3014**. Location specificity in fusion-negative rhabdomyosarcoma driven by cell of origin.

Fieke W. Hoff, BS, University Medical Center Groningen, Groningen, The Netherlands. **Abstract 451**. Proteomic profiling of the unfolded protein response identifies patients benefiting from bortezomib in pediatric acute myeloid leukemia.

Yu Liu, PhD, St. Jude Children's Research Hospital, Memphis, TN. **Abstract 1287**. Exploring somatic DNA structural alteration and aberrant genomic interactions in cancer through GenomePaint.

Palaniraja Thandapani, PhD, New York University School of Medicine, New York, NY. **Abstract 349**. Dynamic 3d chromosomal landscapes in acute leukemia.

2018 AACR-Gerald B. Grindey Memorial Scholar-in-Training Award

This award is presented to the author of a meritorious abstract in the field of preclinical science presented at the AACR Annual Meeting 2018. The late Dr. Grindey was a dedicated member of the AACR and a distinguished scientist at Eli Lilly and Company. The Gerald B. Grindey Memorial Fund was established in his honor and has been entrusted to the AACR to be used toward educational programs for early-career scientists engaged in preclinical cancer research.

Jennifer E. Howes, PhD, Vanderbilt University, Nashville, TN. **Abstract 865**. Small molecule-mediated modulation of Ras elicits inhibition of phospho ERK signaling through negative feedback on SOS1.

2018 AACR-Get Your Rear in Gear Philadelphia Scholar in Training Awards supported by the Colon Cancer Coalition

Get Your Rear in Gear Philadelphia has graciously donated funds to the AACR to support early-career investigators who will be presenting meritorious abstracts on colorectal cancer research at the AACR Annual Meeting 2018.

Ann-Marie Baker, PhD, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom. **Abstract 5368**. The evolutionary history of human colitis-associated colorectal cancer.

Susheel Bhanu Busi, MS, University of Missouri, Columbia, MO. **Abstract 4987**. Biofilm-producing sulfate-reducing bacteria suppress tumor burden in a rat model of colon cancer.

Rochelle E. Fletcher, BA, University of Pittsburgh School of Medicine, Pittsburgh, PA. **Abstract 267**. Nonsteroidal anti-inflammatory drugs induce ER stress- and BID-dependent immunogenic cell death to suppress colorectal tumorigenesis.

Antja-Voy Hartley, BS, Indiana University School of Medicine, Indianapolis, IN. **Abstract 3346**. PRMT5-mediated methylation of YBX1 regulates NF- κ B activity in colorectal cancer.

Andreana N. Holowatyj, PhD, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT. **Abstract 5249**. Crosstalk between visceral adipose and tumor tissue in colorectal cancer patients: Molecular signals driving host-tumor interaction.

Amriti R. Lulla, PhD, Fox Chase Cancer Center, Philadelphia, PA. **Abstract 3908**. miR-3132 induces TRAIL and cell death in mutant p53-expressing cancer cells.

Kazuhito Sato, MD, PhD, The University of Tokyo, Tokyo, Japan. **Abstract 3394**. Actionable fusion kinases in microsatellite instability-high colorectal cancers.

Li Xia, PhD, Stanford University, Stanford, CA. **Abstract 4334**. Linked read whole genome sequencing reveals pervasive chromosomal level instability and novel rearrangements in brain metastases from colorectal cancer.

2018 AACR Scholar-in-Training Awards in Memory of William Maness

The Estate of William Maness has graciously donated funds in his memory to the AACR to support early-career investigators who will be presenting meritorious abstracts on melanoma research at the AACR Annual Meeting 2018.

Julien Ablain, PhD, Boston Children's Hospital, Boston, MA. **Abstract 93**. Tissue-specific CRISPR in zebrafish identifies *PVRL1* as a novel metastasis suppressor gene in melanoma.

Emily Z. Keung, MD, The University of Texas MD Anderson Cancer Center, Houston, TX. **Abstract 5711**. The impact of combination oral azacitidine (CC-486) + pembrolizumab (PEMBRO) on the immune infiltrate in metastatic melanoma (MM).

Bradley D. Shields, BS, University of Arkansas for Medical Sciences, Little Rock, AR. **Abstract 2037**. E-cadherin enhances immune control of metastatic melanoma.

David M. Woods, PhD, NYU Langone Health, New York, NY. **Abstract 612**. Nivolumab-induced changes associated with patient outcomes are disparate in metastatic melanoma patient Tregs versus conventional T cells.

Hanlin Zeng, PhD, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA. **Abstract 5518**. Bi-allelic loss of *CDKN2A* initiates melanoma invasion and metastasis via E2F1-BRN2 axis.

2018 AACR-MEG Scholar-in-Training Awards

These awards are for authors of meritorious abstracts in molecular epidemiology that will be presented at the AACR Annual Meeting 2018, supported by the Molecular Epidemiology Working Group (MEG) of the AACR. The mission of MEG is to increase knowledge about cancer and chronic disease etiology, thereby promoting the prevention and treatment of cancer, and the improvement of public health. In addition to travel support, award recipients receive a free one-year membership to the Working Group.

Jihye Kim, PhD, Harvard T.H. Chan School of Public Health, Boston, MA. **Abstract 4945**. Absolute risk prediction models for pancreatic cancer.

Xiaoliang Wang, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA. **Abstract 2965**. Functionally informed genome-wide interaction analysis of nonsteroidal anti-inflammatory drugs on colorectal cancer risk.

Lang Wu, PhD, Vanderbilt University School of Medicine, Nashville, TN. **Abstract 2969**. Genetically predicted blood protein biomarkers and prostate cancer risk: an analysis in over 140,000 European descendants.

2018 AACR-Prostate Cancer Foundation Scholar-in-Training Awards

The Prostate Cancer Foundation has graciously donated funds to the AACR to support early-career investigators who will be presenting meritorious abstracts on advanced prostate cancer at the AACR Annual Meeting 2018.

Mark P. Labrecque, PhD, University of Washington, Seattle, WA. **Abstract 1092**. Defining the molecular phenotypes of metastatic castration-resistant prostate cancer sensitive to FGF pathway inhibition.

Michelle K. Naidoo, BA, Hunter College and The Graduate Center of the City University of New York, New York, NY. **Abstract 503**. MicroRNA-1205 as a tumor suppressor in castration resistant prostate cancer.

Abhijit Parolia, BS, University of Michigan, Ann Arbor, MI. **Abstract 975**. Functional CRISPR screen towards identifying novel epigenetic co-factors of oncogenic AR-activity.

2018 AACR-Pezcoller Foundation Scholar-in-Training Awards

The Pezcoller Foundation supports these awards to enhance participation in the programs and activities of the AACR by early-career investigators residing in Europe and to provide these outstanding Scholar-in-Training Awardees with an opportunity to share their research findings with the international cancer research community at the AACR Annual Meeting.

Ilijana Bajrami, PhD, The Institute of Cancer Research, London, United Kingdom. **Abstract 2986**. E-cadherin/ROS1 inhibitor synthetic lethality in breast cancer.

Priya Chudasama, PhD, German Cancer Research Center, Heidelberg, Germany. **Abstract 4336**. Integrative genomic and transcriptomic analysis of leiomyosarcoma.

Vincent Faugeroux, PhD, Institut Gustave Roussy, Villejuif, France. **Abstract 5600**. Establishment and characterization of a unique circulating tumor cells-derived xenograft (CDX) in prostate cancer.

Keaton Ian Jones, MD, University of Oxford, Oxford, England. **Abstract 998**. Radiation-induced immunosuppressive macrophages limit CD8 T-cell mediated tumor killing.

Alessandra Tuccitto, MS, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. **Abstract 3517**. Targeting pH regulators to modulate human hepatocellular carcinoma microenvironment.

Lindy L. Visser, MS, Netherlands Cancer Institute, Amsterdam, The Netherlands. **Abstract 4348**. In depth molecular analysis of 183 primary DCIS lesions and 78 subsequent invasive breast cancers.

2018 AACR-SIC Scholar-in-Training Awards

The AACR-SIC Scholar-in-Training Awards are a partnership between the AACR and the Società Italiana di Cancerologia (SIC, the Italian Cancer Society). The AACR and SIC sponsor these awards to enhance participation by early-career investigators who are members of SIC, and to provide these outstanding Scholar-

in-Training Awardees with an opportunity to share their research findings with the international cancer research community at the AACR Annual Meeting.

Francesca Bizzaro, MS, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy. **Abstract 2816**. Patient derived ovarian cancer xenograft (OC-PDX) to study the response of the PARP inhibitor olaparib.

Carmine Carbone, PhD, University of Verona, Verona, Italy. **Abstract 3501**. Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling.

Montserrat Climent Salarich, PhD, Italian Institute of Technology, Genova, Italy. **Abstract 4410**. miRNA-34a sensitizes triple-negative breast cancer cells to paclitaxel reducing cancer stem cell population and lung colonization.

Alessandra De Feo, PhD, Rizzoli Orthopaedic Institute, Bologna, Italy. **Abstract 3549**. Exosome-mediated transfer of sh-CD99 is sufficient to modulate cell differentiation in Ewing sarcoma.

Marta Di Martile, PhD, IRCCS Regina Elena National Cancer Institute, Rome, Italy. **Abstract 5**. The histone acetyltransferase inhibitor CPTH6 impairs tumor angiogenesis acting on both endothelial and cancer cells.

Sara Pagotto, PhD, G. d'Annunzio University, Chieti-Pescara, Italy. **Abstract 3313**. Epigenetic biomarkers of prognosis in stage IIA colon cancer.

Geny Piro, PhD, University of Verona, Verona, Italy. **Abstract 973**. MEKK3 sustains EMT and stemness in pancreatic cancer by regulating YAP and TAZ transcriptional activity.

Ilenia Segatto, PhD, CRO of Aviano, National Cancer Institute, Aviano, Pordenone, Italy. **Abstract 1460**. Stathmin regulates mammary gland morphogenesis and tumorigenesis.

2018 AACR-Takeda Oncology Scholar-in-Training Awards

Takeda Oncology has graciously donated funds to support early-career investigators who will be presenting meritorious abstracts at the AACR Annual Meeting 2018.

Francesca S. Amoroso, PhD, Queen's University Belfast, Belfast, United Kingdom. **Abstract 839**. Treatment and signaling contexts for the application of the imipridone ONC201 to prostate cancer cells.

Natalia Baran, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX. **Abstract 1875**. Oxidative metabolism as a novel therapeutic target to eradicate T-ALL with mitochondrial complex I inhibitor IACS-010759.

Debasish Boral, MD, PhD, Houston Methodist Research Institute, Houston, TX. **Abstract 3264**. Targeting bone marrow-resident dormant CTCs to overcome metastasis.

Daniele Chaves Moreira, Pharm, PhD, University of Pennsylvania, Philadelphia, PA. **Abstract 5416**. Isolation of the PAX8 transcriptional complex to identify novel therapeutic vulnerabilities for ovarian cancer.

Hannah G. Cheriyan, BS, University of Michigan, Ann Arbor, MI. **Abstract 5156**. RhoC decreases tight junction stabilization in breast cancer cells, revealing a potential therapeutic target.

Lionel Tat Wei Chia, MS, Johns Hopkins University, School of Medicine, Baltimore, MD. **Abstract 3352**. HMGA1 chromatin remodeling protein induces *HOXB13* to drive cancer stem cell properties and tumor progression in prostate cancer models.

Marimar de la Cruz Bonilla, BS, The University of Texas MD Anderson Cancer Center, UTHealth Graduate School of Biomedical Sciences, Houston, TX. **Abstract 4164**. Fasting protects mice from lethal radiation by promoting small intestinal stem cell survival.

Maria Chiara Fontana, MS, University of Bologna, Institute of Hematology L. & A. Sèragnoli, Bologna, Italy. **Abstract 1872**. Pharmacological inhibition of WIP1 sensitizes AML cells to MDM2 inhibitors.

Lydia Giannopoulou, MS, National and Kapodistrian University of Athens, Athens, Greece. **Abstract 4587**. *ESR1* methylation in primary tumors and paired circulating tumor DNA of patients with high-grade serous ovarian cancer.

Amanda C. Herrmann, BS, The University of Texas MD Anderson Cancer Center, Houston, TX. **Abstract 5612**. Evaluating the cytotoxic effectiveness of a novel TCR-like bispecific T cell engager targeting the PR1/HLA-A2 leukemia antigen.

Andrew T. Holdbrooks, BS, University of Alabama at Birmingham, Birmingham, AL. **Abstract 2334**. Sialylation of the TNFR1 death receptor promotes cancer cell survival.

Eui-Jun Kim, PhD, University of Wisconsin-Madison, Madison, WI. **Abstract 4313**. Methylated BAF155 promotes cancer metastasis by cooperating with BRD4 to potentiate genes addicted to super-enhancers.

Seung Hyeon Kim, MS, Seoul National University, Seoul, South Korea. **Abstract 69**. Chemotherapy-induced cancer cell death diminishes therapeutic efficacy through heme oxygenase-1-mediated inactivation of M1-like tumor associated macrophages.

Estefania Labanca, MS, The University of Texas MD Anderson Cancer Center, Houston, TX. **Abstract 2870**. A specific pan-FGFR inhibitor has antitumor activity against prostate cancer patient derived xenografts, PDX, expressing high FGFR1.

Jun Ho Lee, BS, Ulsan National Institute of Science and Technology, Ulsan, Republic of Korea. **Abstract 1519**. TonEBP promotes hepatocellular carcinogenesis, recurrence, and metastasis.

Yasmin Leshem, MD, National Cancer Institute, Bethesda, MD. **Abstract 1767**. Synergy between intratumoral immunotoxin and systemic anti-CTLA-4 promotes massive inflammation and leads to complete regression of tumors in mice.

Zhida Liu, PhD, University of Texas Southwestern Medical Center, Dallas, TX. **Abstract 2752**. EGFR tyrosine kinase inhibitor limits tumor relapse through enhancing anti-tumor T cell responses.

Sofia Mastoraki, MS, University of Athens, Athens, Greece. **Abstract 4577**. *ESR1* methylation: A liquid biopsy-based epigenetic assay for the follow up of patients with metastatic breast cancer receiving endocrine treatment.

Maeve Mullooly, PhD, Royal College of Surgeons, Dublin, Ireland. **Abstract 3260**. Utilizing digital pathology to understand breast epithelial characteristics of benign breast disease among women undergoing diagnostic image-guided breast biopsy.

Trine Line Hauge Okholm, MS, Aarhus University Hospital, Aarhus, Denmark. **Abstract 1299**. Circular RNA expression is abundant and correlated to aggressiveness in early-stage bladder cancer.

Emma Pailler, PhD, Gustave Roussy - INSERM U981, Villejuif, France. **Abstract 3654**. Identification of resistance mutations to crizotinib through circulating tumor cell (CTC) analysis in *ALK*-rearranged non-small-cell lung cancer (NSCLC).

Mohammad Aminur Rahman, PhD, University of Bergen, Bergen, Norway. **Abstract 2928**. Bortezomib sensitizes glioblastoma with unmethylated *MGMT* promoter to temozolomide-chemotherapy through *MGMT* depletion and abrogated autophagy flux.

Naveen Ramesh, MS, The University of Texas MD Anderson Cancer Center, Houston, TX. **Abstract 3665**. Longitudinal monitoring of prostate cancer evolution by plasma genome sequencing.

Laura Schubert, BA, University of Colorado Denver, Aurora, CO. **Abstract 1842**. Novel *KIF5B-RET*+ NSCLC cell lines demonstrate differential responses to RET inhibitors.

Brittany A. Simone, DO, Thomas Jefferson University Hospital, Philadelphia, PA. **Abstract 71**. Caloric restriction promotes antitumor immunity through polarization of intratumoral macrophages to M1 phenotype via downregulation of miR-21.

Thu H. Truong, PhD, University of Minnesota Masonic Cancer Center, Minneapolis, MN. **Abstract 532**. PELP1 and AIB1 (SRC-3) complexes promote cancer stem cell-associated phenotypes in ER+ breast cancer models.

Marijn T.M. van Jaarsveld, PhD, Max Planck Institute for Molecular Genetics, Berlin, Germany. **Abstract 4286**. Tissue-specific preference for ATM or ATR pathway activation determines DNA damage outcome and provides insights in cancer predisposition.

Vivek Verma, PhD, Lombardi Comprehensive Cancer Center, Georgetown University Medical School, Washington, DC. **Abstract 4717**. MAP kinase inhibition induces metabolic reprogramming in T-cells leading to induction of stem cell memory CD8 cells that enhance potency of adoptive cell therapy and anti-OX40 antibody.

Annie A. Wu, BS, Johns Hopkins Medical Institution, Baltimore, MD. **Abstract 611**. PD-1-based combination immunotherapy reinvigorates CD8⁺ T cells in metastatic pancreatic cancer patients with improved survival.

Jun Zhang, MS, The University of Hong Kong, Hong Kong. **Abstract 3079**. Epstein Barr virus-encoded LMP1 reprograms glucose metabolism to enhance cell motility in nasopharyngeal epithelial cell.

2018 AACR Scholar-in-Training Award supported by the Barb Tullio Run Against Lung Cancer

Funds have been graciously donated from the organizers of the Barb Tullio Run Against Lung Cancer to the AACR to recognize an outstanding young investigator for meritorious work in lung cancer research and to support attendance to the 2018 AACR Annual Meeting 2018.

Masanori Fujii, MD, PhD, Beth Israel Deaconess Medical Center, Boston, MA. **Abstract 5440**. Role of tyrosine phosphorylation of β -catenin in EGFR-mutant lung cancer.

2018 AACR-Warner Fund Scholar-in-Training Awards

The Warner Fund has graciously donated funds to the AACR to support early-career investigators who will be presenting meritorious work relating to cholangiocarcinoma.

Akiyoshi Kasuga, MD, Keio University, School of Medicine, Tokyo, Japan. **Abstract 4083.** Intrahepatic cholangiocarcinoma and gallbladder carcinoma mouse model based on transplantation of syngeneic tumor-initiating cells.

Jisce R. Puik, BS, VU University Medical Center, Amsterdam, Noord-Holland, The Netherlands. **Abstract 493.** Circulating biliary tract microRNA signature discriminates cholangiocarcinoma from pancreatic cancer.

2018 AACR Scholar-in-Training Award in Memory of Dr. Richard L. Welsh

Gifts made in memory of Dr. Richard L. Welsh have been graciously donated to support a young investigator presenting a high-quality abstract in renal cancer at the AACR Annual Meeting 2018.

Khalid Saeed, MS, University of Helsinki, Helsinki, Finland. **Abstract 2199.** Establishment and high-throughput drug testing of multiple patient-derived cells from each renal cancer; intratumor heterogeneity of drug response and implications for precision medicine.

2018 AACR Scholar-in-Training Award in Honor of Cathy Whalen

Gifts made in honor and support of Cathy Whalen have been graciously donated to support a young investigator presenting a high-quality abstract in bile duct cancer at the AACR Annual Meeting 2018.

Sunyoung S. Lee, MD, PhD, Roswell Park Comprehensive Cancer Institute, Buffalo, NY. **Abstract 2095.** Automated mapping and analysis of stromal cells in tumor microenvironment in pancreatic adenocarcinoma and cholangiocarcinoma using deep learning.